Company: IMCR
Filing Date: 2025-03-24
Form Type: PRE 14A
Source: 0001140361-25-010035
Chunk: 44

Company: Immunocore Holdings plc
Filing Date: 2025-03-24
Form: PRE 14A
Chunk 44
---
 Exchange Act. The audit committee’s responsibilities include:

| • | determining whether to appoint, reappoint or remove any auditors, and making recommendations to the board of directors to be put to the shareholders for approval at the annual general meeting; |

| • | reviewing audit plans, the adequacy of staffing and fees, whilst overseeing the negotiation and execution of any engagement letters on our behalf; |

| • | at least annually, assessing the qualifications, performance, and independence of the auditors, or in the case of prospective auditors, before they are engaged; |

| • | overseeing the policies and procedures governing how we may employ individuals who are or once were employed by the auditors; |

| • | reviewing results of the annual audit, audited financial statements, periodic and annual reports, earnings announcements, proxy report, accounting principles and policies; |

| • | evaluating management’s cooperation with the auditors during their audit examination; |

| • | reviewing and reporting on policies on financial risk management and assessment; |

| • | reviewing the audit plan of any internal audit team; |

| • | reviewing the scope, design, adequacy and effectiveness of internal controls; |

31

TABLE OF CONTENTS

| • | overseeing our policies, procedures, plans and information technology systems designed to ensure and manage risks relating to the security, confidentiality, availability and integrity of information, as well as the operation and effectiveness thereof; |

| • | reviewing correspondence with regulators or governmental agencies that raise material issues regarding our financial statements or accounting policies; |

| • | overseeing procedures for receiving, retaining and investigating complaints; |

| • | monitoring compliance with our Code of Business Conduct and Ethics and related party transactions rules; and |

| • | reviewing with management legal and regulatory compliance and any actual, pending, or threatened legal or financial matters that could significantly affect our business or financial statements or as otherwise deemed appropriate by the audit committee. |

Report of the Audit Committee of the Board of Directors The material in this report is not “soliciting material,” is not deemed “filed” with the SEC and is not to be incorporated by reference in any filing of Immunocore under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. The audit committee has reviewed and discussed the audited financial statements for the fiscal year ended December 31, 2024 with our management. The audit committee has discussed